Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3433 | SARS-CoV-2 plasma Wiki | 1.00 |
| drug3014 | Plitidepsin 2.5 mg/day Wiki | 1.00 |
| drug3013 | Plitidepsin 2.0 mg/day Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| D018352 | Coronavirus Infections NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
In December 2019, Wuhan, in Hubei province, China, became the center of an outbreak of pneumonia of unknown cause. In a short time, Chinese scientists had shared the genome information of a novel coronavirus (SARS-CoV-2) from these pneumonia patients and developed a real-time reverse transcription PCR (real-time RT-PCR) diagnostic assay. Given no specific antiviral therapy for COVID-19 and the ready availability of plitidepsin as a potential antiviral agent, based on pre-clinical studies, this randomized, parallel and proof of concept trial will evaluate the safety of three doses of plitidepsin in patients hospitalized with COVID-19.
Description: Percentage of patients with Neutropenia ≥ grade 3
Measure: Frequency of occurrence of Neutropenia ≥ grade 3 Time: Up to 31 daysDescription: Percentage of patients with Thrombocytopenia ≥ grade 3
Measure: Frequency of occurrence of Thrombocytopenia ≥ grade 3 Time: Up to 31 daysDescription: Percentage of patients with Anemia ≥ grade 3
Measure: Frequency of occurrence of Anemia ≥ grade 3 Time: Up to 31 daysDescription: Percentage of patients with Lymphopenia ≥ grade 3
Measure: Frequency of occurrence of Lymphopenia ≥ grade 3 Time: Up to 31 daysDescription: Percentage of patients with CPK increase ≥ grade 3
Measure: Frequency of occurrence of CPK increase ≥ grade 3 Time: Up to 31 daysDescription: Percentage of patients with Increase ALT and / or AST ≥ grade 3
Measure: Frequency of occurrence of Increase ALT and / or AST ≥ grade 3 Time: Up to 31 daysDescription: Percentage of patients with Increase total bilirubin or direct bilirubin ≥ grade 3
Measure: Frequency of occurrence of Increase total bilirubin or direct bilirubin ≥ grade 3 Time: Up to 31 daysDescription: Percentage of patients with Neurotoxicity ≥ grade 3
Measure: Frequency of occurrence of Neurotoxicity ≥ grade 3 Time: Up to 31 daysDescription: Percentage of patients with QT-QTc interval extension ≥ grade 3
Measure: Frequency of occurrence of QT-QTc interval extension ≥ grade 3 Time: Up to 31 daysDescription: Percentage of patients with Other adverse events ≥ grade 3
Measure: Frequency of occurrence of Other adverse events ≥ grade 3 Time: Up to 31 daysDescription: Percentage of patients in whom treatment cannot be completed and the reasons.
Measure: Percentage of patients in whom treatment cannot be completed. Time: At 3 days from the first dose of study treatmentDescription: Percentage of patients with adverse events.
Measure: Percentage of patients with adverse events. Time: Up to 31 daysDescription: Percentage of patients with serious adverse events.
Measure: Percentage of patients with serious adverse events. Time: Up to 31 daysDescription: Percentage of patients with ECG abnormalities.
Measure: Percentage of patients with ECG abnormalities. Time: Up to 31 daysDescription: Percentage of change in the viral load of SARS-CoV-2 from baseline.
Measure: Change in the viral load of SARS-CoV-2 Time: Up to 31 daysDescription: Time from inclusion/randomization to date of negative PCR test for COVID-19
Measure: Time to negative PCR test for COVID-19 Time: Up to 31 daysDescription: Percentage of patients who die during the study
Measure: Mortality Time: Up to 31 daysDescription: Percentage of patients requiring invasive mechanical ventilation and / or ICU admission
Measure: Percentage of patients requiring invasive mechanical ventilation and / or ICU admission Time: Up to 31 daysDescription: Percentage of patients requiring non-invasive mechanical ventilation
Measure: Percentage of patients requiring non-invasive mechanical ventilation Time: Up to 31 daysDescription: Percentage of patients requiring oxygen therapy
Measure: Percentage of patients requiring oxygen therapy Time: Up to 31 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports